Perez Villardon, BGarcia Bellon, AMJimenez Rubio, CRubio Alcaide, APerez Benito, LRamirez Marrero, MADe Mora Martin, MDe Teresa Galvan, E2016-10-032016-10-032016-06Perez Villardon B; Garcia Bellon AM, Jimenez Rubio C; Rubio Alcaide A, Perez Benito L, Ramirez Marrero MA, et al. Oral direct anticoagulants in the treatment of nonvalvular atrial fibrillation. Results of the daily clinical practice. Haematologica. 2016; 101 (s1) P410,0390-6078http://hdl.handle.net/10668/2439Atrial fibrillation (AF) is the most common arrhythmia. It leads to significant morbidity and mortality. The new oral anticoagulants (NOAC) represent an improvement compared with standard treatment (vitamin K antagonists (AVK)) in the prevention of thromboembolic complications in patients with non-valvular AF.enAnticoagulantesFibrilación atrialFibrinolíticosHumanosVitamina KMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::AnticoagulantsMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Arrhythmias, Cardiac::Atrial FibrillationMedical Subject Headings::Chemicals and Drugs::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Hematologic Agents::Fibrinolytic AgentsMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Chemicals and Drugs::Polycyclic Compounds::Polycyclic Hydrocarbons, Aromatic::Naphthalenes::Naphthoquinones::Vitamin Kconference presentationopen access1592-8721